Due to the HER2 3+ phenotype of the excised tumour, the patient additionally completed adjuvant one-year trastuzumab therapy, in line with recommendations for the treatment of HER2 3+ breast cancers [31]. This evidence concerns the gene ERBB2 and breast carcinoma.